10mg 24hs 10, ; . When GCs other than HC are used, the bioequivalence dose ratio is based upon anti-inflammatory potency, because other clinical equivalence tables are not yet available. Thus, replacement therapy with synthetic GCs frequently uses improper doses, but even "physiologic doses" may impair growth velocity and restrict final height 12 ; . Several mechanisms may be involved in this scenario: suppression of pituitary GH secretion, reduction of tissue sensitivity to GH, inhibition of IGF-1 bioactivity and decreased collagen synthesis 13 ; . Reliable results using small HC doses and mineralocorticoid replacement with fludrocortisone have been recently reported, when combined with antiandrogens flutamide ; and aromatase inhibitors testolactone ; 14 ; . However, this complex and expensive multi-drug scheme is demanding for routine use, especially in third-world countries. As an alternative option to treat 21OHD, longacting synthetic GC analogues may suppress ACTH more efficiently 7, 15, 16 ; . Prednisolone PD ; has a molecular structure that resembles that of cortisol, with the C1-C2 double bond determining a longer half-life and possibly permitting single daily dose administration. In addition, its convenient commercially available formulation homogeneous oral solution ; permits fine therapeutic adjustments. In the present study, we have extended our previous short-term observations 17 ; for one year in order to evaluate potential clinical benefits of PD therapy in patients with 21OHD. The structure of studied compounds, their determined melting points, as well as, molar adsorption coefficients in phosphate buffer with pH 7.0 are in the Table 1. In ultraviolet region of spectra the compounds show three absorption bands at wavelength 214 nm 1 nm, 236 nm 1 nm and 278 nm 1 nm, respectively. The relative values of surface local anaesthetic activity Up are expressed by efficiency index against cocaine as a standard, where Up of cocaine is equal 1. The values Ui represent the efficiency index against procaine at infiltration local anaesthesia, where Ui of procaine is equal 1 [12]. We have used the digitized images provided in four test runs with UCLA undergraduates, and the pattern of results has been absolutely consistent. Typical data reveal a sex difference in corrected SNB counts F 1, 32 ; 70.42, p 0.0001 ; , a main effect for treatment F 1, 32 ; 43.86, p 0.0001 ; , and a significant sex x treatment interaction F 1, 32 ; 40.84, p 0.0001 ; refer to Figure 5A ; . Post-hoc orthogonal comparisons on the typical data revealed that control males had significantly more SNB neurons than did any other group all comparisons p 0.0001 ; but that there were no other significant comparisons among the four groups all p 0.05 ; . In our test runs, we consistently found a sex difference in the size of SNB neurons F 1, 32 ; 53.97, p 0.0001 ; but neither an effect of Flutamidw F 1, 32 ; 1.88, p 0.05 ; nor a significant sex x treatment interaction F 1, 32 ; 0.17, p 0.05; refer to Figure 5B ; . The nuclear sizes of neurons showed a similar pattern with a significant sex difference F 1, 32 ; 8.01, p 0.01 ; but no treatment effect F 1, 32 ; 0.70, p 0.05 ; and no sex by treatment interaction F 1, 32 ; .50, p 0.05; refer to Table 1 ; . Corrected counts of the RDLN neurons from the digitized images typically revealed no significant differences due to sex F 1, 32 ; 0.47, p 0.05 ; , treatment F 1, 32 ; 0.85, p 0.05 ; , or sex x treatment interaction F 1, 32 ; 0.19, p 0.05; refer to Figure 6A ; . RDLN soma sizes similarly revealed no significant difference due to sex F 1, 32 ; 0.30, p 0.05 ; , treatment F 1, 32 ; 0.44, p 0.05 ; , or sex x treatment interaction F 1, 32 ; 0.87, p 0.05; refer to Figure 6B ; . RDLN nuclear sizes showed a similar pattern with no difference due to sex F 1, 32 ; .079, p 0.05 ; , treatment F 1, 32 ; 0.78, p 0.05 ; , or sex x treatment interaction F 1, 32 ; 0.90, p 0.05; refer to Table 1. Studies by nimh have shown this drug to be particularly effective for depression in patients with bipolar illness, unlikely to cause manic swings, and less sedating than placebo meaning it is usually a little activating.

T B E1 SWORT DRUG INTERACTIONS Hypericum perforatum ; 26, 33, 36, A L . TJ St. John's Wort induces or potentially induces the metabolism of the following substrates, which may decrease serum level of drug: 1. P-450 2C9 or CYP 2C9 substrate Speculative-direct significance not established--additional research needed ; 2. P-450 1A2 or CYP 1A2 substrate Significance not established--additional research needed ; 3. P-450 3A4 or CYP450 3A substrate Interaction of drugs cleared by CYP450 3A reported clinical significance established ; 4. Induction of P-glycoprotein 8. P-450 2D6 or CYP 2D6 substrate Speculative-direct significance not established--additional research needed ; Other Interactions: 5. Case reports Clinical studies 6. Possible serotonin excess 7. Increased risk of photosensitivity 5-Hydroxy-Tryptophan 6 Achromycin 7 Actiq 3 Accutane 7 Adriamycin 3 Agenerase 3, 4 Adalat 3, 4 Alfenta 3 Alfentanil 3 Allegra PGP 3 Alprazolam 3, 5 no study interaction - small sample size, short duration ; Amaryl 1 Ambien 3 Amerge 6 Amiodarone 3 Amitriptyline 5, 7, 8 Amlodipine 3 Amprenavir 3, 4 Anafranil 8 Ansaid 1 Antidepressants 6 Aricept 8 Atorvastatin 3 Aventyl 8 Avita 7 Benzodiazepines 3 Certain Long Acting ; Bepridil 3 Beta Blockers, Various Betimol 8 Biaxin 3 Bisoprolol 8 Calan 2, 3, 4 Calcium Channel Blockers 3 Carbamazepine 3 Cardene 3 Cardizem 3 Cataflam 1 Celexa 6 Chlorpromazine 7 Cisapride 3 Citalopram 6 Clarithromycin 3 Claritin 3 Clomipramine 8 Clonazepam 3 Clozapine 2, 8 Clozaril 2 Codeine 8 Cognex 2 Cordarone 3 Corticosteroids 3 Cortisone 3 Cortone 3 Coumadin 1, 2, 3 Cozaar 1, 3 Crixivan 3 Cyclobenzaprine 2, 3, 8 Cyclophosphamide 3 Cyclosporine 3, 4, 5 Cytoxan 3 Dapsone 1, 3 Decadron 3, 4 Delavirdine 3 Deltasone 3 Desipramine 8 Desoxyn 8 Desyrel 6 Dexamethasone 3, 4 Dextromethorphan 3, 5, 8 No study interaction small sample size, short duration ; Diazepam 2, 3 Diclofenac 1 Digitoxin 4 Digoxin 4, 5 Dilantin 1 Diltiazem 3 Disopyramide 3 Donepezil 8 Doxorubicin 3 Doxycycline 7 Duragesic 3 Dynacirc 3 Efavirenz 3 Effexor 6 Elavil 2, 3, 7 Elixophyllin 2 Erythromycin 3, 4 Estrogens 2, 3 Ethinyl Estradiol 3, 5 Etopophos 3 Etoposide 3 Eulexin 3 Felbamate 7 Felbatol 7 Feldene 1, 7 Felodipine 3 Fentanyl 3 Fexofenadine 3, 4 Finasteride 3 Flecainide 8 Flexeril 2, 3 Flurbiprofen 1 Rlutamide 3 Fluvastatin 1 Fluoxetine 6, 8 Fluvoxamine 6 Fortovase 3, 4 Gantanol 1 Glimepiride 1 Glipizide 1 Grifulvin 7 Grisactin 7 Griseofulvin 7 Glucotrol 1 Granisetron 3 Haldol 2, 3 Haloperidol 2, 3, 8 Hydrocodone 8 Ifex 3 Ifosfamide 3 Ilotycin 3, 4 Ibuprofen 1 Imipramine 2, 3, 8 Imitrex 6 Imodium 4 Inderal 2 Indinavir 3, 5 Interferon 7 Ivermectin 4 Invirase 3, 4 Isoptin 2, 3, 4 Isotretinoin 7 Isradipine 3 Ketoconazole 3, 4 Klonopin 3 Kytril 3 L-Tryptophan 6 Lamisil 3, 4 Lanoxin 4 Lescol 1 Lidocaine 3 Lipitor 3 Loperamide 4 Lopressor 3 Loratadine 3 Losartan 1, 3 Lovastatin 3 Luvox 6 Macrolide Antibiotics 3 Maois 6 Maprotiline 8 Maxalt 6 Medrol 3 Mellaril 8 Mellaril-S 8 Methadone 3, 8 Methadose 3 Methylprednisolone 3 Metoprolol 3, 8 Mevacor 3 Mexiletine 8 Mibefradil 3 Miconazole 3 Midazolam 3 Monistat 3 Morphine 4, 8 Ms Contin 4 Mycobutin 3 Naprosyn 1 Naratriptan 6 Nardil 6 Naproxen 1 Nefazodone 3, 5 1 case report-elderly patient ; Nelfinavir 3, 4 Nevirapine 3 Nicardipine 3 Nifedipine 3, 4 Nimodipine 3 Nimotop 3 Nisoldipine 3 Nizoral 3, 4 Nolvadex 1, 3, 4 NNRTIS metabolized similar to protease inhibitors ; Norpramin 8 Nortriptyline 8 Norpace 3 Norvasc 3 Norvir 3, 4 Nsaids 1 Olanzapine 2 Oncovin 3, 4 Ondansetron 3, 4 Oral Contraceptives 3, 5 Orinase 1 Oxycodone 8 Oxycontin 8 Oxyir 8 Paclitaxel 3, 4 Pamelor 8 Paracetamol 2, 3 Paroxetine 6, 8 Paxil 6 Percolone 8 Phenelzine 6 Phenprocoumon 5 Phenytoin 1 Photofrin 7 Pimozide 3 Piroxicam 1, 7 Plendil 3 Porfirmer 7 Posicor 3 Prednisone 3 Procardia 3, 4 Prograf 3 Propafenone 8 Propranolol 2, 8 Propulsid 3 Proscar 3 Protease Inhibitors 3, 4 Prozac 6 Quinaglute 3, 4 Quinine 3 Quinidine 3, 4 Renova 7 Requip 2 Reserpine may sleep ; Rescriptor 3 Restoril 3 Retin-A 7 Retinoic Acid 3 Rifabutin 3 Risperdal 8 Risperidone 8 Ritonavir 3, 4 Rizatriptan 6 Ropinirole 2 Roxicodone 8 Rythmol 2, 3, 8 Sandimmune 3 Saquinavir 3, 4 Seldane 3, 4 removed from U.S. market in 1998 ; Sertraline 3, 5 4 case reports-elderly patients ; Serzone 3 Sildenafil 3 Simvastatin 3 Ssris 6 Steroids 3 Sufenta 3 Sufentanil 3 Sular 3 Sulfa Drugs 7 Sulphamethoxazole 1 Sular 3 Sulfa Drugs 7 Sulphamethoxazole 1 Sumatriptan 6 Sumycin 7 Tacrine 2 Tacrolimus 3 Tambocor 8 Tamoxifen 1, 3, 4 Taxol 3, 4 Tegretol 3 Temazepam 3 Teniposide 3 Terbinafine 3, 4 Terfenadine 3, 4 Not in the U.S. market as of '98 ; Testosterone 3 Tetracycline 7 Theophylline 2, 5 Thioridazine 8 Thorazine 7 Timolol 8 Timoptic 8 Tofranil 2, 3 Tolbutamide 1 Toprol 3 Tramadol 8 Trazodone 6, 8 Tretinoin 7 Triptans 6 Troleandomycin 3 Ultram 8 Valium 2, 3 Vascor 3 Velban 3, 4 Venlafaxine 6, 8 Vepesid 3 Verapamil 2, 3, 4 Verelan 2, 3, 4 Versed 3 Viagra 3 Vibramycin 7 Vinblastine 3, 4 Vincasar 3, 4 Vincristine 3, 4 Viracept 3, 4 Viramune 3 Voltaren 1 Vumon 3 Warfarin 1, 2, 3, Xanax 3 no study interaction - small sample, short duration Xylocaine 3 Zebeta 8 Ziac 8 Zocor 3 Zofran 1, 3, 4 Zolmitriptan 6 Zolpidem 3 Zoloft 3 Z mg 6 oi TM Zonegran 3 Zonisamide 3 Zyprexa 2 and efavirenz. 6.5. Requirements for Completed but Not-Dispensed Prescriptions: In cases where Contractor's pharmacy completes a prescription, but the client fails to pick up the prescribed medicines, Contractor's pharmacy may: 6.5.1. Forward the prescribed drugs to the client, either by mail or by personal delivery after confirmation with the client. In such situations Contractor may bill the County the applicable rates for those drugs, including one dispensing fee for each prescription. The billing date will be the date the drugs are forwarded to the client. Contractor may not bill the County or the client any delivery charges. Contractor must maintain clear and concise records that confirm the prescribed drugs were delivered to the client; or 6.5.2. Return the undelivered drugs to inventory. In such situations Contractor may not bill the County any amount for either the drugs or the dispensing fee. 6.6. Formulary Compliance Requirements: Prescriptions dispensed under this contract shall only be formulary medications and products dispensed and or delivered to eligible clients. Approved drug exceptions will be treated in the same manner as formulary prescriptions. Partially filled, non-formulary drugs dispensed in after-hours situations, pending completion of an exception request will be treated in the same manner as partially filled formulary prescriptions. The Department may request documentation that evidences the actual receipt of dispensed drugs by eligible clients. 6.7. Pharmacy Location Requirements: Contractor must at a minimum provide a pharmacy network consisting of pharmacies that meet the geographic requirements in Exhibit III and exclude the Health care network, small business enterprise, and Public Health Department pharmacies. 6.8. Paper Formulary Requirement: In situations, where Contractor's pharmacies cannot confirm formulary compliance on an on-line basis, the pharmacies must use a paper copy of the formulary. 6.9. Innovation in Dispensing: The Department wants to reduce pharmacy dispensing costs while providing appropriate drug therapy to our clients. There are many ways to reduce pharmacy dispensing costs to include central filling, mail order for chronic medications refills, less dispensing locations, federal pricing under section 340B of the Public Health Service Act enacted by section 602 of Public Law 102-585, the Veterans Health Care Act of 1992, prescription order entry, etc. Proposers should identify their methods to reduce pharmacy dispensing costs when answering the questions in the proposal section of this RFP. 6.10. Detailed Description of Required Pharmacy Services: Pharmacy services, under this contract, begin when an eligible client presents a prescription at a Contractor's pharmacy. Each Contractor's pharmacy shall confirm the following information prior to dispensing any prescribed medication, over-the-counter OTC ; medicines, diabetic supply items including but not limited to electronic blood glucose monitoring machines, lancets, and strips ; and corresponding diabetic related medical supply items such as alcohol and cotton balls ; : Client eligibility, including restrictions and co-payment amounts; and That prescribed drugs are included in the Department's formulary including prescriptions for OTC drugs and diabetic equipment supplies or that a drug exception request has been submitted and approved for the drugs, equipment, and supplies; and Conformity with the requirements of Contractor's DUR program.

Uman and laboratory animal studies have demonstrated a sexual dimorphism in hypertension.1 Gender differences have been observed in various hypertensive animal models, with male rats having higher blood pressure than female rats, 2 6 including the transgenic rat TGR mREN2 ; 27 with an overactive renin-angiotensin system RAS ; .7, 8 Evidence is accumulating that androgens may play an important role in gender-associated differences in cardiovascular pathology. We have previously demonstrated that androgens contribute not only to the development of malignant hypertension but also to the associated end-organ damage in transgenic male TGR mREN2 ; 27 rats with overactive RAS.9 Females produce androgens as well, which act on specific receptors.10 Women with hyperandrogenism are considered to be at increased risk for cardiovascular disease.1115 Based on a prospective literature survey, it has been recently hypothesized that relative androgen excess is a key factor explaining the increased risk of cardiovascular disease in interpausal women.16 In the present study, we hypothesized that endogenous androgens may participate in the development of hypertension and end-organ damage in female TGR mREN2 ; 27 rats. Androgen blockade was achieved by treatment with the antagonist Flutamide, and blood pressure BP ; as well as end-organ damage, RAS, and sex hormones were evaluated and femara. FLUOR-A-DAY FLUORINSE Fluorometholone Fluoromtholone Fluoromtholone actate de ; Fluorometholone Acetate Fluorouracil Fluorure de sodium FLUOTIC Tab Co. Orl 20mg Fluoxtine chlorhydrate de ; Fluoxetine Hydrochloride Flupenthixol chlorhydrate de ; Flupenthixol dcanoate de ; Flupenthixol Hydrochloride Flupentixol decanoate Fluphnazine chlorhydrate de ; Fluphnazine dcanoate de ; Fluphenazine decanoate Fluphenazine Hydrochloride Flurazpam chlorhydrate de ; Flurazepam Hydrochloride Flurbiprofen Flurbiprofne Flu6amide Flu6amide Fluticasone Propionate Fluticasone propionate Fluvastatin sodique Fluvastatin Sodium Fluvoxamine malate de ; Fluvoxamine Maleate FML Dps Gttes Oph 0.1% FML FORTE Sus Susp. Oph 0.25% Folic Acid Folique acide ; FORADIL Aem Am Inh 12mcg Foradil Aem 12g Formoterol Formotrol Formoterol Fumarate FORTAZ Pws Pds. Inj 500mg FORTAZ Pws Pds. Inj 1gm FORTAZ Pws Pds. Inj 2gm FORTOVASE Cap Caps Orl 200mg Fosamax Tab 10mg Fosamax Tab 40mg Fosamax Tab 70mg Fosamprenavir Fosfomycin Tromethamine Fosinopril sodique Fosinopril Sodium FRAGMIN Liq Liq Inj 25, 000IU FRAGMIN prefilled syringes ; Liq Liq Inj 25, 000IU Framycetin Sulfate Framycetin Sulfate Dexamethasone Sodium-Sulfobenzoal Gramicidin Framycetin Sulfate Esculin Dibucaine Hydrochloride Hydrocortisone Acetate Framyctine sulfate de. Cathy Gibson, R.Ph. Cost of Care Pharmacist Clinical Services.

The active metabolite of flutamide, in vivo , at steady-state plasma concentrations of 1556 to 2284 ng ml, is 92% to 94% bound to plasma proteins. Also in this case, stat3 could not reverse the antagonistic activity of flutamide on a wild-type ar.
Adverse Event Rate % ITT ; Goserelin 0 0% ; . Goserelin and flutamide 2 18 and raloxifene. Goodwill The excess of the purchase price over the fair value of the net assets "goodwill" ; of an acquired subsidiary is amortized using the straight-line method over five years. Goodwill amounts at March 31, 2003 were 6, 272 million $52, 273 thousand ; , net of amortization of 1, 568 million $13, 068 thousand ; . Reserve for Retirement Benefits Employees of the Companies terminating their employment either voluntarily or upon reaching the mandatory retirement age are entitled to severance payments based on the rate of pay at the time of termination, length of service and certain other factors. Previously, the Company accounted for retirement benefits based on the present value of projected future retirement benefits attributable to employee services rendered by the fiscal year end, less amounts funded under a contributory pension plan. Effective April 1, 2000, the Company and domestic subsidiaries adopted a new accounting standard for employees' retirement benefits and accounted for the liability for retirement benefits based on projected benefit obligations and plan assets at the balance sheet data. The entire transitional obligation of 5, 048 million, determined as of April 1, 2000, was charged to income. As a result, net periodic benefit costs, as compared with the prior method, increased and income before income taxes and minority interests decreased by 4, 178 million. Actuarial gains or losses are amortized primarily by the straight-line method over a period within the average remaining years of service of the employees generally five years ; . Effective April 1, 2002, the Company adopted a method of amortization over the period starting in the year in which the actuarial gains or losses were incurred. Previously, amortization of actuarial gains and losses started in the year after the year in which incurred. The effect of this change was to increase retirement benefit expenses for the fiscal year ended March 2003 by 6, 191 million and decrease income before income taxes and minority interests by an equivalent amount, compared to amounts that would have resulted if the previous method had been applied. Retirement allowances for directors and corporate auditors are recorded to state the liability at the amount that would be required if all directors and corporate auditors retired at each balance sheet date. These amounts are paid subject to approval of the shareholders in accordance with the Japanese Commercial Code. Stock and Bond Issue Costs Stock and bond issue costs are charged to income as incurred. Foreign Currency Transactions The Companies have adopted "Accounting Standards for Foreign Currency Transactions". All short-term and long-term monetary receivables and payables denominated in foreign currencies are translated into Japanese yen at the current exchange rates at the balance sheet date. Revenue and expense items denominated in foreign currencies are translated using the rate on the date of the transaction. Related exchange gains or losses are credited or charged to income as incurred. Foreign Currency Financial Statements The financial statements of overseas subsidiaries and affiliates are translated into Japanese yen by the following methods as set forth by an accounting standard for foreign currency translation. 578-581. 15. Kesaniemi, Y.A and T. A. Miettinen. 1987. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur. J. Clin. Invest. 17: 191-195. 16. Gylling, H., and T. A. Miettinen. 1992. Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes. J. Lipid Res. 33: 1361-1371. 1 . Vuoristo, M., H. Vaananen, and T. A. Miettinen. 1992. 7 Cholesterol malabsorption in pancreatic insufficiency: effects of enzyme substitution. Gastmentemlogy. 102: 647-653. 18. Tilvis, R. S., and T A. Miettinen. 1986. Serum plant . sterols and their relation to cholesterol absorption. Am. J. Clin. Nutr. 43: 92-97. 1 . Gruenke, L. D., and L. C. Craig. 1978. The synthesis of 9 cholesterol-2, 2, 4, Labelled Compd. & Radiopham. J. 16: 495-500. 20. Brown, H. L., W. Gard, and K. T. Lin. 1971. Saturated secondary alcohols also give nonepimerised ketones in good yield when ether is used instead of acetone. J. Org. Chem. 36: 387-390. 21. Kircher, H. W., and F. U. Rosenstein. 1972.Hydrogenation : of stigmasterol. Lipids. 8 101-105. W. 22. Souci, S. W., Fachmann, and H. Kraut. 1990. Food Composition and Nutrition Tables 1989A990. Wissenschaftliche Verlagsgesellschaft mbH. Stuttgart, Germany. 23. Davidson, N. O., E. H. Ahrens, Jr., D. J. Bradlow, D. J. McNamara, T. S. Parker, and P. Samuel. 1980. Unreliability of tritiated cholesterol: studies with [1, 2-3H]- and [24, 25-3H]cholestero1 man. Pmc. Natl. Acad. Sci. USA. 77: in 2255-2259. 24. Grundy, S. M. 1982. Role of isotopes for determining absorption of cholesterol in man. In Lipoprotein Kinetics and Modeling. M. Berman, B. Howard, and S. M. Grundy, editors. Academic Press, New York. 363-371. 25. Ferezou, J., and F. Chevallier. 1982 parative methods of quantifying fecal neutral sterols in rats and humans after intravenous [ 14C], [3H]or [2H]cholesterollabeling. Biochim. Biophys. Acta. 713: 678-683. 26. Ferezou, J., J. Rautureau, T. Coste, E. Gouffier, and F. Chevallier. 1982. Cholesterol turnover in human plasma lipoproteins: studies with stable and radioactive isotopes. Am. J. Clin. Nutr. 36: 235-244. 27. Taylor, C. B., B. Mikkelson, J. A. Anderson, and D. T. Forman. 1966. Human serum cholesterol synthesis measured with the deuterium label. Arch. Pnthol. 81: 213-231. 28. Ferezou, J.%T. Coste, and F. Chevallier. 1981. Origins of neutral sterols in human feces studied by stable isotope labeling D and 13C ; . Existence of an external secretion of cholesterol. Digestion. 21: 232-243. 29. Ferezou, J., J. C. Sulpice, T. Coste, and F. Chevallier. 1982. Origins of neutral sterols in human feces studied by stable isotope labeling D and 13C ; . Digestion. 25: 164-172. 30. Virelizier, H., and R. Hagemann. 1980. Use of stable isotopes in the study of human cholesterol metabolism. In Advances in Mass Spectrometry. A. Quale, editor. Heyden & Son Ltd., London, GB. 8B: 1155-1158. Members. If you would like to enroll in or learn more about the program, please contact the Health Services Department at 800-2518191, extension 495 or ask for Cyndy Moore.
Type: DR4. Thus, it was concluded that most drug-induced lupus would be avoided if women who have the DR4 HLA type and are slow acetylators simply never took procainamide, hydralazine, or other drugs suspected of inducing an LLS. In the future, we may expect that knowing one's HLA type may be as common and as vital as knowing one's red blood cell RBC ; antigen types is at this time.